FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage - NCH-201803

Rheinische Friedrich-Wilhelms-Universitaet Bonn0 个研究点目标入组 334 人开始时间: 2024年5月14日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Male or female subjects, equal or older than 18 years old, Written consent to participate in the study by the patient or his legal representative (emergency inclusion by next of kin or consultant physician under the responsibility of the principal investigator is possible)), Confirmed diagnosis of aneurysmal SAH and onset within 48 hours before inclusion

•SAH due to any other cause than aneurysm rupture (e.g. traumatic, arteriovenous malformation (AVM), fistula, dissection), Known ulceration in the gastro-intestinal tract, History of gastro-intestinal bleeding, Long-term treatment with corticosteroids prior SAH, Any condition that, in the judgement of the Investigator, could impose hazards to the patient if study therapy is initiated or affects the participation of the patient in the study, Patients with obvious evidence of irreparable brainstem or thalamic injury, Patients with foreseeable difficulties to attend follow-ups adequately, Subjects with a physical or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial, Current positive pregnancy test (e.g. ß-HCG test in serum), Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure, Severe infectious diseases (in discretion of the local investigator by clinical and laboratory parameters e.g. CRP, PCT, WBC, IL-6), Known angle-closure or open angle glaucoma

发起方

Rheinische Friedrich-Wilhelms-Universitaet Bonn